Literature DB >> 31294181

Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes.

Stephen T Abedon1.   

Abstract

Bacteriophages can be used as antibacterial agents as a form of biological control, e.g., such as phage therapy. With active treatment, phages must "actively" produce new virions, in situ, to attain "inundative" densities, i.e., sufficient titers to eradicate bacteria over reasonable timeframes. Passive treatment, by contrast, can be accomplished using phages that are bactericidal but incapable of generating new phage virions in situ during their interaction with target bacteria. These ideas of active versus passive treatment come from theoretical considerations of phage therapy pharmacology, particularly as developed in terms of phage application to well-mixed cultures consisting of physically unassociated bacteria. Here I extend these concepts to bacteria which instead are physically associated. These are bacteria as found making up cellular arrangements or bacterial microcolonies-collectively, clonal bacterial "clumps". I consider circumstances where active phage replication would be required to effect desired levels of bacterial clearance, but populations of bacteria nevertheless are insufficiently prevalent to support phage replication to bacteria-inundative densities across environments. Clumped bacteria, however, may still support active treatment at more local, i.e., sub-millimeter, within-clump spatial scales, and potential consequences of this are explored mathematically. Application is to the post-harvest biocontrol of foodborne pathogens, and potentially also to precise microbiome editing. Adequate infection performance by phages in terms of timely burst sizes, that is, other than just adsorption rates and bactericidal activity, thus could be important for treatment effectiveness even if bacterial densities overall are insufficient to support active treatment across environments. Poor phage replication during treatment of even low bacterial numbers, such as given food refrigeration during treatment, consequently could be problematic to biocontrol success. In practical terms, this means that the characterization of phages for such purposes should include their potential to generate new virions under realistic in situ conditions across a diversity of potential bacterial targets.

Entities:  

Keywords:  active treatment; bacteriophage therapy; foodborne pathogens; host range; inundation threshold; microbiome editing; passive treatment; phage therapy; proliferation threshold

Year:  2017        PMID: 31294181      PMCID: PMC6604992          DOI: 10.3934/microbiol.2017.3.649

Source DB:  PubMed          Journal:  AIMS Microbiol        ISSN: 2471-1888


  7 in total

1.  Evaluation of Phage Delivery Systems on Induced Motile Aeromonas Septicemia in Oreochromis niloticus.

Authors:  Kathleen May C Gordola; Fatima Alesandra U Boctuanon; Raylene Audrey A Diolata; Maria Bernadette D Pedro; Tracey Antaeus D Gutierrez; Rey Donne S Papa; Donna May D Papa
Journal:  Phage (New Rochelle)       Date:  2020-12-16

2.  Pathways to Phage Therapy Enlightenment, or Why I Have Become a Scientific Curmudgeon.

Authors:  Stephen T Abedon
Journal:  Phage (New Rochelle)       Date:  2022-06-16

Review 3.  Further Considerations on How to Improve Phage Therapy Experimentation, Practice, and Reporting: Pharmacodynamics Perspectives.

Authors:  Stephen T Abedon
Journal:  Phage (New Rochelle)       Date:  2022-06-16

Review 4.  Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective.

Authors:  Valéry Daubie; Houssein Chalhoub; Bob Blasdel; Hafid Dahma; Maya Merabishvili; Tea Glonti; Nathalie De Vos; Johan Quintens; Jean-Paul Pirnay; Marie Hallin; Olivier Vandenberg
Journal:  Front Cell Infect Microbiol       Date:  2022-09-21       Impact factor: 6.073

5.  Bacteriophage treatment of carbapenemase-producing Klebsiella pneumoniae in a multispecies biofilm: a potential biocontrol strategy for healthcare facilities.

Authors:  Ariel J Santiago; Maria L Burgos-Garay; Leila Kartforosh; Mustafa Mazher; Rodney M Donlan
Journal:  AIMS Microbiol       Date:  2020-02-26

6.  Safety and Efficacy of a Phage, kpssk3, in an in vivo Model of Carbapenem-Resistant Hypermucoviscous Klebsiella pneumoniae Bacteremia.

Authors:  Yunlong Shi; Yuan Peng; Yixin Zhang; Yu Chen; Cheng Zhang; Xiaoqiang Luo; Yajie Chen; Zhiqiang Yuan; Jing Chen; Yali Gong
Journal:  Front Microbiol       Date:  2021-05-20       Impact factor: 5.640

7.  Improving Phage-Biofilm In Vitro Experimentation.

Authors:  Stephen T Abedon; Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Matthew B Sullivan
Journal:  Viruses       Date:  2021-06-19       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.